top of page

The Importance of Early Detection: Advocating for ALD Newborn Screening

Adrenoleukodystrophy (ALD) is a rare genetic disorder that can cause severe neurological and adrenal gland dysfunction. Early detection is critical for the successful treatment of ALD, and newborn screening can identify the disease before symptoms appear, allowing for early intervention.

Newborn screening is a simple, inexpensive blood test that is performed shortly after birth. The test can detect the presence of certain substances in the blood that are indicative of ALD. If the test comes back positive, further testing can be done to confirm the diagnosis, and treatment can begin immediately.

The benefits of newborn screening for ALD are numerous. Early detection allows for early intervention, which can slow the progression of the disease and improve outcomes for affected children. Treatment options include a diet that is low in very long chain fatty acids (VLCFAs), the use of Lorenzo's Oil, a dietary supplement that helps to break down VLCFAs, and bone marrow transplantation.

While newborn screening for ALD is not yet universal, advocacy efforts are underway to expand screening programs. Advocacy groups, such as the ALD Connect Foundation and the ALD Alliance, are working to raise awareness about the importance of early detection and to advocate for the inclusion of ALD in newborn screening programs.

In addition to advocacy efforts, families affected by ALD can also play a role in promoting newborn screening. By sharing their stories and experiences with healthcare providers and policymakers, they can help to raise awareness about the importance of early detection and the benefits of newborn screening.

Overall, newborn screening for ALD is an important tool for early detection and intervention. Advocacy efforts and increased awareness can help to expand screening programs and ensure that all children with ALD have access to early detection and treatment.

3 views0 comments


bottom of page